Affiliation:
1. National Medical Research Centre of Endocrinology
Abstract
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms constituting about 0.5 % of all cancer cases. In recent years, there has been a significant increase in the incidence of NETs, which is primarily due to the active development and improvement of medical imaging technologies. Successful treatment and prognosis for patients with NETs strongly depend on the stage of the disease. One of the effective methods of visualization and staging NETs in nuclear medicine is somatostin receptor scintigraphy (SRS), which is based on the use of partial somatostatin receptor agonists labeled with radioactive isotopes. The article presents an analysis of 55 patients with NETs of various localizations who underwent scintigraphy and SPECT/CT. Radiopharmaceutical was used as a tracer for SRS. It was prepared on the basis of a lyophilisate developed by Polatom (Poland) — Tektrotyd, labeled with 99mTc. According to the results of the study SRS with 99mTc-Tektrotyd is informative in the topical diagnosis of NETs, especially when PET/CT scan with 68Ga-labeled peptides is not available. Sensitivity varies depending on the NET localization. It is necessary to continue researches on the diagnostic value of SRS with 99mTc-Tektrotyd for tumors, in the pathogenesis of which somatostatin receptors play a significant role.
Publisher
Infra-M Academic Publishing House
Subject
Nuclear Energy and Engineering
Reference14 articles.
1. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80 Suppl 1:3-7. DOI: 10.1159/000080731., Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80 Suppl 1:3-7. DOI: 10.1159/000080731.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377., Yao JC, Hassan M, Phan A, et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377.
3. Williams E. The Classification of Carcinoid Tumours. Lancet. 1963;281(7275):238-9. DOI: 10.1016/s0140-6736(63)90951-6., Williams E. The Classification of Carcinoid Tumours. Lancet. 1963;281(7275):238-9. DOI: 10.1016/s0140-6736(63)90951-6.
4. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al, editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010. p. S13-S14., Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al, editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010. p. S13-S14.
5. Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016;40(9):1192-202. DOI: 10.1097/PAS.0000000000000662., Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016;40(9):1192-202. DOI: 10.1097/PAS.0000000000000662.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献